Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Pass Below 50 Day Moving Average of $1.51

Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.51 and traded as low as $1.40. Pieris Pharmaceuticals shares last traded at $1.41, with a volume of 108,837 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 19th.

Pieris Pharmaceuticals Trading Up 0.7 %

The stock’s fifty day moving average price is $1.51 and its 200 day moving average price is $1.24. The stock has a market cap of $104.92 million, a P/E ratio of -3.00 and a beta of 1.17.

Institutional Investors Weigh In On Pieris Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in PIRS. JPMorgan Chase & Co. grew its holdings in Pieris Pharmaceuticals by 149.9% in the 1st quarter. JPMorgan Chase & Co. now owns 63,643 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 38,179 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth about $32,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth about $1,263,000. BlackRock Inc. lifted its position in shares of Pieris Pharmaceuticals by 1.6% in the 1st quarter. BlackRock Inc. now owns 1,338,437 shares of the biotechnology company’s stock worth $4,055,000 after purchasing an additional 21,150 shares during the period. Finally, Blair William & Co. IL lifted its position in shares of Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 10,760 shares during the period. Institutional investors own 47.31% of the company’s stock.

About Pieris Pharmaceuticals

(Get Rating)

Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.